Explore

Trendline Trendline
Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment

Diakonos Oncology Receives FDA Fast Track Designation for Melanoma Treatment
Rapid Read Rapid Read
Colon Cancer Immunotherapy Breakthrough Keeps Patients Cancer-Free for Nearly Three Years

Colon Cancer Immunotherapy Breakthrough Keeps Patients Cancer-Free for Nearly Three Years

A UK-led clinical trial has demonstrated that a short course of immunotherapy before surgery can keep colorectal cancer patients cancer-free for nearly three years. The NEOPRISM-CRC study found that nine weeks of pembrolizumab treatment before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer. The trial's success challenges the standard approach of surgery followed by chemotherapy, suggesting that starting with immunotherapy may offer longer-lasting protection against cancer recurrence.
Trendline Trendline
Delphi Diagnostics Validates Endocrine Activity Index for Breast Cancer Prognosis

Delphi Diagnostics Validates Endocrine Activity Index for Breast Cancer Prognosis

Delphi Diagnostics Validates Endocrine Activity Index for Breast Cancer Prognosis
Trendline Trendline
Caris Life Sciences Launches AI-Powered Test for Breast Cancer Recurrence Risk

Caris Life Sciences Launches AI-Powered Test for Breast Cancer Recurrence Risk

Caris Life Sciences Launches AI-Powered Test for Breast Cancer Recurrence Risk
Trendline Trendline
LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline

LTZ Therapeutics Secures $38 Million to Advance Immunotherapy Pipeline
Rapid Read Rapid Read
Melanoma Research Alliance Invests $18.4 Million in Global Research Initiatives

Melanoma Research Alliance Invests $18.4 Million in Global Research Initiatives

The Melanoma Research Alliance (MRA) has announced a significant investment of $18.4 million to fund global research initiatives aimed at advancing melanoma detection and treatment. This funding will support 30 discovery-stage research grants and initiatives such as the RARE Melanoma Research Consortium and the Melanoma Biorepository. These efforts are designed to address complex and underserved forms of melanoma, with the goal of improving patient outcomes. MRA's investment spans leading academic and medical institutions across the United States and five other countries, reinforcing its role as a global leader in melanoma research.
Trendline Trendline
MRD Testing Revolutionizes Breast Cancer Risk Assessment

MRD Testing Revolutionizes Breast Cancer Risk Assessment

MRD Testing Revolutionizes Breast Cancer Risk Assessment
Trendline Trendline
Guardant Health's Guardant360 CDx Approved by FDA for Advanced Breast Cancer Treatment

Guardant Health's Guardant360 CDx Approved by FDA for Advanced Breast Cancer Treatment

Guardant Health's Guardant360 CDx Approved by FDA for Advanced Breast Cancer Treatment
Trendline Trendline
Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics

Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics

Foundation Medicine to Launch Pharmacogenetic Offering in Partnership with Fulgent Genetics
Trendline Trendline
Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial

Summit Therapeutics Faces Setback as Ivonescimab Misses Early Survival Goal in Lung Cancer Trial
Rapid Read Rapid Read
Melanoma Research Alliance Invests $18.4 Million in Global Research to Advance Melanoma Breakthroughs

Melanoma Research Alliance Invests $18.4 Million in Global Research to Advance Melanoma Breakthroughs

The Melanoma Research Alliance (MRA) has announced its largest annual global investment of $18.4 million to fund melanoma research. This investment supports 30 discovery-stage research grants and advances the RARE Melanoma Research Consortium and the Melanoma Biorepository. The initiative aims to unlock insights into complex and underserved forms of melanoma. Despite advances in early detection and treatment, melanoma remains the deadliest form of skin cancer, with rising incidence rates. The MRA's funding focuses on innovative research areas, including circadian immunodynamics, AI-powered insights, and drug resistance.
Trendline Trendline
Agendia to Present FLEX Study Data on Genomic Profiling in Breast Cancer

Agendia to Present FLEX Study Data on Genomic Profiling in Breast Cancer

Agendia to Present FLEX Study Data on Genomic Profiling in Breast Cancer